Fast, Cost-Effective Single Cell RNA Sequencing

There is a growing desire to answer questions about the genome at the level of the individual cell. Single cell RNA sequencing technologies promise to make a significant impact on research and clinical studies; however, most scRNA-seq technologies require centralization and pooling, which can be inefficient and unwieldy. The G4™ Sequencing Platform addresses these challenges and enables researchers to generate low-cost, accurate scRNA-seq results much faster than any other sequencer on the market.

Powerful Sequencing with Seamless Integration

The G4 Sequencing Platform features novel chemistry and advanced engineering, designed to provide labs with unmatched operational efficiency and industry-leading run times.  The G4 integrates seamlessly into existing NGS workflows and is well suited for single cell RNA sequencing.

Key scRNA-Seq capabilities:

  • Rapid SBS enables cost-efficient delivery of 1–8 single cell RNA sequencing samples in 12–15 hours.*
  • The G4 delivers highly accurate scRNA-Seq data comparable to the leading high-throughput platform.

*Assuming 150M reads per sample

Fast, Cost-Effective Single Cell RNA Sequencing

Our application note shows how the G4 delivers scRNA-Seq data that is highly comparable to that of the Illumina® NextSeq 2000, with the added benefits of lower costs and faster turnaround.

High Quality scRNA-Seq Performance Equivalent to Illumina®

A comparison of scRNA-Seq data generated by the G4 and NextSeq 2000 platforms shows:

  • Nearly identical cell type and unsupervised cluster labels with comparable lineage marker expression profiles
  • Strong correlation of pseudo-bulk profiles and differential gene expression patterns for major PBMC cell types

Download Single Cell RNA-Seq Application Note

Please provide your information to download the app note.

Download the Single Cell Application Note

Please fill out the information below to download the application note.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note